| __timestamp | AstraZeneca PLC | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 13324000000 | 35942000 |
| Thursday, January 1, 2015 | 11451000000 | 40028000 |
| Friday, January 1, 2016 | 9739000000 | 45853000 |
| Sunday, January 1, 2017 | 10543000000 | 53816000 |
| Monday, January 1, 2018 | 10362000000 | 60804000 |
| Tuesday, January 1, 2019 | 11848000000 | 77252000 |
| Wednesday, January 1, 2020 | 11693000000 | 45736000 |
| Friday, January 1, 2021 | 15680000000 | 50323000 |
| Saturday, January 1, 2022 | 18955000000 | 143526000 |
| Sunday, January 1, 2023 | 18025000000 | 149182000 |
| Monday, January 1, 2024 | 20532000000 | 154335000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. AstraZeneca PLC, a leader in global healthcare, has consistently invested heavily in Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, AstraZeneca's SG&A expenses have shown a steady upward trend, peaking in 2022 with a 42% increase from 2016. This reflects their aggressive market expansion and strategic acquisitions.
Conversely, Halozyme Therapeutics, Inc., a smaller biotech firm, has demonstrated a more modest growth in SG&A expenses. Despite a significant 315% increase from 2014 to 2023, their expenses remain a fraction of AstraZeneca's, highlighting their focused and efficient operational model.
This comparison underscores the diverse strategies within the pharmaceutical sector, where scale and focus dictate financial priorities.
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Bristol-Myers Squibb Company
AstraZeneca PLC or Bio-Techne Corporation: Who Manages SG&A Costs Better?
AstraZeneca PLC vs Viking Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: AstraZeneca PLC vs PTC Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights
Sarepta Therapeutics, Inc. or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation